MST1R and prostate cancer: MST1R, on the other hand, has primarily been detected in various tumors, including pancreatic cancer (Babicky et al., 2019), nasopharyngeal carcinoma (Dai et al., 2016), prostate cancer (Batth et al., 2021), and breast cancer (Millar et al., 2020).